ZOMDFOTCPharmaceutical PreparationsUS GAAP · USD

Zomedica Corp.

Zomedica Corp. is a U.S.-based veterinary health company that develops and commercializes diagnostic and therapeutic products for companion animals. Its portfolio includes the TRUFORMA, PulseVet, Assisi, TRUVIEW, VetGuardian, and VETIGEL product lines, sold through direct and indirect channels in the United States and international markets.

Kysy yhtiöstä
Liikevaihto32,0milj. USD
+17,4 %v/v
Liikevoitto (EBIT)−84,4milj. USD
−65,2 %v/v
EBIT-marginaali−263,4%
−76,2 %-yks.v/v
Nettotulos−81,9milj. USD
−74,2 %v/v
Vapaa kassavirta−18,2milj. USD
+36,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100−75−50−2502550milj. USD2020: 0,00 milj. USD2020: EBIT −17 milj. USD20202021: 4,1 milj. USD2021: EBIT −21 milj. USD20212022: 19 milj. USD2022: EBIT −22 milj. USD20222023: 25 milj. USD2023: EBIT −32 milj. USD20232024: 27 milj. USD2024: EBIT −51 milj. USD20242025: 32 milj. USD2025: EBIT −84 milj. USD202532−84
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Zomedica Corp.

Liiketoiminta

Osuus liikevaihdosta
Diagnostic platforms25 %

Veterinary diagnostic instruments and assays used in clinic settings, including TRUFORMA.

Therapeutic devices45 %

Non-invasive veterinary treatment systems and related consumables, including PulseVet and Assisi.

Monitoring and connected care10 %

Remote monitoring hardware, subscriptions, and service agreements for animal care.

Consumables and disposables15 %

Recurring consumable products sold alongside installed platforms and devices.

Contract manufacturing and engineering5 %

Engineering and manufacturing-related revenue recognized from third-party work.

Tuotteet

Raportoitu · osuus liikevaihdosta
64,6%28,9%FY2025100 %
  • Consumables Revenue64,6 %
  • Capital Revenue28,9 %
  • Engineering Revenue6,2 %
  • Other0,4 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Zomedica sells primarily to veterinary clinics, hospitals, and animal health practitioners that need diagnostic, therapeutic, and monitoring tools for companion animals. Its installed-base model means customers often buy capital equipment first and then purchase recurring consumables, assays, subscriptions, or service agreements over time.

Veterinary clinics

Buy TRUFORMA, PulseVet, Assisi, and related consumables to perform diagnostics and treatments in-house.

Veterinary hospitals and specialty practices

Use therapeutic and monitoring products for broader case mix and higher-acuity animal care.

Companion animal practitioners

Purchase devices and consumables to support routine and recurring patient care.

International distributors and channel partners

Buy or place products for resale and local market access outside the U.S.

Contract manufacturing customers

Purchase engineering and manufacturing services when Zomedica performs third-party work.

Strategia

Zomedica’s strategy centers on expanding its installed base of veterinary platforms and increasing recurring revenue from consumables, assays, and services. It also emphasizes new assay development for TRUFORMA, broader commercialization of existing products, and selective business development that can add products, capabilities, or manufacturing revenue.

Grow recurring revenue from installed platformsLyhyt aikaväli

The model depends on repeat consumables, assays, and services after device placement.

Expand TRUFORMA assay menuKeskipitkä aikaväli

More assays increase platform utility and support customer adoption and utilization.

Broaden commercialization across product linesLyhyt aikaväli

Selling more products across the portfolio reduces dependence on any single platform.

Pursue selective business developmentKeskipitkä aikaväli

Acquisitions or partnerships can add technology, products, or manufacturing capability.

Maantiede

Q1/2026

Zomedica is headquartered in the United States and reports revenue from both U.S. and international markets. The company also has subsidiaries in Switzerland and Canada, but its functional currency is the U.S. dollar, and its commercial footprint is centered on veterinary customers in North America with additional international sales.

USA84 %
Other countries (US filing)16 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Zomedica’s business depends on successful product adoption, customer retention, and continued consumable usage after device placement, so demand weakness or customer churn can quickly reduce recurring revenue. The company also faces impairment risk on goodwill, intangibles, and equipment, plus typical medtech risks around product development, commercialization, and regulatory execution.

Järjestetty vakavuuden mukaan
Customer return and churn risk on placed capitalKorkea

TRUFORMA-related capital is placed with customers who can return it, which can stop recurring consumable purchases.

Kohdistuu: Installed-base diagnostic and therapeutic products

Impairment of goodwill, intangibles, and equipmentKorkea

Management disclosed sensitivity to assumptions, discount rates, and market conditions that can trigger write-downs.

Kohdistuu: Acquired assets and reporting units

Commercialization and adoption riskKeskitaso

New assays, VETIGEL, and other products must gain traction to support growth.

KohdistuuTRUFORMAVETIGELNew launches
Funding and dilution riskKeskitaso

Future capital needs could require equity issuance or debt, affecting ownership and flexibility.

Kohdistuu: Corporate funding and acquisitions

Regulatory and product development riskKeskitaso

Veterinary diagnostics and therapeutics require ongoing development, validation, and market acceptance.

KohdistuuAssaysDevicesClinical studies
Kysy Clarifolta: Zomedica Corp.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition across multiple product types

The company sells capital equipment, consumables, subscriptions, and services, which may be recognized at different times.

Vaikutus: Can shift revenue between periods and affect comparability

Valuation and payback of placed capital

TRUFORMA-related assets remain on the balance sheet until placed and are assessed against expected future consumable revenue.

Vaikutus: Affects asset carrying values and potential write-downs

Goodwill and intangible asset impairment

Management uses discounted cash flow and market-based valuation methods with sensitive assumptions.

Vaikutus: Can produce material non-cash impairment charges

Property and equipment recoverability

The company evaluates whether equipment can be recovered through expected future revenue over its life.

Vaikutus: May require impairment if utilization or placements disappoint

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Zoetis Inc.

ZTS · Pharmaceutical Preparations

Zymeworks Inc.

ZYME · Pharmaceutical Preparations

Biomerica, Inc

BMRA · In Vitro & In Vivo Diagnostic Substances

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

ZyVersa Therapeutics, Inc.

ZVSA · Pharmaceutical Preparations

Prothena Corporation plc

PRTA · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Zomedica Corp. (OTC) – Pharmaceutical Preparations | Analyysi – Clarifo